Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma
October 13, 2015 at 07:30 AM EDT
Incyte Corporation (Nasdaq: INCY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the ...
